Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orexo, a company that develop products based on its reformulation technologies, targeted at the Specialty Pharmaceutical market, has named Anders Lundstrom as the new CEO of the company to lead its commercial development.
Subscribe to our email newsletter
Most recently, Lundstrom worked as the head of Biogen Idec International Commercial Operations, and was responsible for sales and marketing in 28 countries and through distributors in over 50 countries worldwide.
Prior to joining Biogen Idec, Lundstrom held positions in marketing and sales at AstraZeneca, Janssen-Cilag and Bristol-Myers Squibb.
Orexo chairman of the board Hakan Astrom said Anders Lundström has the perfect profile to be the new CEO of Orexo.
"This is crucial in Orexo’s current strategic phase with increased focus on the development, marketing and sales of proprietary drugs," Astrom said.